Drugs / SRT501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00920556 | Mar 2009 → Nov 2010 | plasma cell myeloma | Sirtris, a GSK Company | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00920803 Comparator | Aug 2008 → Nov 2009 | colorectal neoplasm | Sirtris, a GSK Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SRT501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00920803 ↗ |
| Known as | resveratrol | “A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.” PMID 23205612 ↗ Dec 2012 |
| Route | Oral | “SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.” NCT00920556 ↗ |